Latest news with #ACRV
Yahoo
17-05-2025
- Business
- Yahoo
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company's tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some 'real de-risking clinical data to comfortably' value Acrivon's biomarker-based selection platform. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ACRV: Disclaimer & DisclosureReport an Issue Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating Acrivon Therapeutics Reports Q1 2025 Progress and Financials Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
Oppenheimer lowered the firm's price target on Acrivon Therapeutics (ACRV) to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
15-05-2025
- Business
- Business Insider
Oppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $9.00. The company's shares closed yesterday at $1.14. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -16.2% and a 27.06% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences. Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $11.43. ACRV market cap is currently $37.63M and has a P/E ratio of -0.46. Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.
